{"entity":{"id":"lm-302","kind":"drug","name":"LM-302","aka":[],"tldr":"LM-302 is an experimental antibody-drug conjugate from LaNova Medicines Zhejiang in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.","summary":"LM-302 is an antibody-drug conjugate developed by LaNova Medicines Zhejiang and Shanghai Chia Tai Tianqing Pharmaceutical Technology Development. Its target is Claudin 18.2 (the sponsor names CLDN18.2 (Claudin 18.2)). The sponsor states: LM-302 is an antibody-drug conjugate targeting CLDN18.2, evaluated in combination with tislelizumab versus tislelizumab plus chemotherapy in previously untreated, CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov describes the intervention as: The LM-302 injection is an ADC drug targeting CLDN18.2. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07385703 (Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma), in gastric & gastro-oesophageal junction cancer. The largest, NCT07385703, plans to enrol 752 participants with primary completion expected 2028-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of LM-302","url":"https://clinicaltrials.gov/search?intr=LM-302"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":["cldn18-2"],"drugs":[],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07385703","nct05934331"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"ADC","mechanism":"LM-302 is an antibody-drug conjugate targeting CLDN18.2, evaluated in combination with tislelizumab versus tislelizumab plus chemotherapy in previously untreated, CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lm-302/","neighbours":{"cancer":[{"id":"gastric-cldn18-2-positive","kind":"cancer","name":"Claudin 18.2-positive gastric cancer","route":"/cancers/gastric-cldn18-2-positive/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"trial":[{"id":"nct05934331","kind":"trial","name":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","route":"/trials/nct05934331/"},{"id":"nct07385703","kind":"trial","name":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct07385703/"},{"id":"nct07108504","kind":"trial","name":"Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct07108504/"}]}}